The main risks are external gates rather than product relevance. Export controls can reduce mix and timing, Zeiss and other bottleneck suppliers can cap output, and a handful of customers drive
backlog conversion. ASML can handle normal
capex cyclicality, but at today’s
premium valuation even a delay-heavy year in
High-NA or China can hurt the stock more than the business.